Azithromycin in Patients with Cystic Fibrosis Chronically Infected with Pseudomonas aeruginosa: A Randomized Controlled Trial

JAMA

Volumn 290, Issue 13, 2003, Pages 1749-1756

  Saiman, Lisa ^a,i   Marshall, Bruce C ^b,h   Mayer Hamblett, Nicole ^c,d,e   Burns, Jane L ^d,e   Quittner, Alexandra L ^f   Cibene, Debra A ^e   Coquillette, Sarah ^e   Fieberg, Ann Yunker ^e   Accurso, Frank J ^g   Campbell III, Preston W ^h  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e Cyst Fibrosis Ther Dev N R Ctr   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g Children's Hospital Colorado   (United States)

^h Cystic Fibrosis Foundation   (United States)

ⁱ Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DORNASE ALFA; IBUPROFEN; INTERLEUKIN 8; PLACEBO; PREDNISONE; TOBRAMYCIN; ANTIINFECTIVE AGENT; PANCREATIC ELASTASE;

ABDOMINAL PAIN; ACHROMOBACTER; ADOLESCENT; ADULT; ANOREXIA; ARTICLE; ASPERGILLUS; BURKHOLDERIA CEPACIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DYSPNEA; FATIGUE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HEADACHE; HEMOPTYSIS; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; MYCOBACTERIUM; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SORE THROAT; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; VERTIGO; VOMITING; WEIGHT GAIN; WHEEZING; BLOOD; CHRONIC DISEASE; FORCED EXPIRATORY FLOW; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHRONIC DISEASE; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY FLOW RATES; HOSPITALIZATION; HUMANS; INTERLEUKIN-8; MALE; PANCREATIC ELASTASE; PROPORTIONAL HAZARDS MODELS; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0141816759     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.13.1749     Document Type: Article

References (34)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:521-588.
2. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med. 1996; 335:179-188.
3. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax. 1997;52:915-918.
4. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829-1832.
5. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998;351:420.
6. Anstead MI, Kuhn RJ, Hartford LH, et al. Effect of chronic azithromycin on lung function in cystic fibrosis [abstract]. Pediatr Pulmonol. 1999;19:283-284.
7. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978-984.
8. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002;57: 212-216.
9. Ichimiya T, Takeoka K, Hiramatsu K, et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy. 1996;42:186-191.
10. Tateda K, Ishii Y, Matsumoto T, et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin and azithromycin. Antimicrob Agents Chemother. 1996;40:2271-2275.
11. Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother. 1998;41:37-46.
12. Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127:725-734.
13. Ramsey BW, Pepe MS, Quan JM, et al, for Cystic Fibrosis Inhaled Tobramycin Study Group. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
14. Fuchs HJ, Borowitz DS, Christiansen DH, et al, for the Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331: 637-642.
15. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848-854.
16. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115.
17. Shepard RM, Duthu GS, Ferraina RA, Mullins MA. High-performance liquid chromatographic assay with electrochemical detection for azithromycin in serum and tissues. J Chromatogr. 1991;565:321-337.
18. Quittner AL, Sweeny S, Watrous M, et al. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol. 2000;25:403-414.
19. Quittner AL, Buu A, Davis MA, Modi AC. Application of factor analysis and random effects modeling to examine gender differences in HRQOL [abstract]. Qual Life Res. 2002;11:661.
20. Modi AC, Quittner AL. Validation of a disease specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003; 28:535-546.
21. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1995;152:1107-1136.
22. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis center in the United States. Clin Infect Dis. 1998;27:158-163.
23. Whittier S, Hopfer RL, Knowles MR, Gilligan PH. Improved recovery of mycobacteria from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol. 1993;31:861-864.
24. Sagel SD, Kapsner R, Osberg I, et al. Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. Am J Respir Crit Care Med. 2001;164:1425-1431.
25. Diggle P, Heagerty P, Liang KY, Zeger SL. Analysis of longitudinal data. In: Diggle P, ed. Oxford Statistical Science Series. 2nd ed. Oxford, England: Oxford University Press; 2002:117-130.
26. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42:121-130.
27. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345-352.
28. Iglewski BH. The role of quorum sensing in azithromycin sensitivity of P aeruginosa. Pediatr Pulmonol. 2002;(suppl 24):146.
29. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2002;46:1105-1107.
30. App EM, Konig K, Duffner U, et al. The effects of azithromycin therapy on sputum inflammation in CF lung disease [abstract]. Am J Respir Crit Care Med. 2000;161:758.
31. Tai S, Sudo E, Sun F, et al. Effect of azithromycin treatment on sputum rheology in cystic fibrosis patients [abstract]. Pediatr Pulmonol. 1999;19:264.
32. Altschuler EL. Azithromycin, the multidrug-resistant protein, and cystic fibrosis [letter]. Lancet. 1998;351:1286.
33. Olivier KN, Weber DJ, Wallace RJ, et al. Nontuberculous mycobacteria, I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med. 2003; 167:828-834.
34. Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria, II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med. 2003;167:835-840.